|
Patent landscape, scope, and claims: |
What is the Scope of U.S. Patent 5,698,225?
U.S. Patent 5,698,225, granted on December 16, 1997, covers a novel pharmaceutical composition. It claims a method for treating or preventing diseases with a specific class of compounds, emphasizing the chemical structure, formulation, and their application for therapeutic purposes.
The key technical scope includes:
- A pharmaceutical composition comprising a specific active ingredient, a carrier, and optional excipients.
- The chemical structure of the active ingredient, which falls within a defined class of compounds characterized by certain substituents and functional groups.
- The method of administering these compounds to treat particular medical conditions, including specified dosage regimes and routes of delivery.
The patent's claims are directed mainly at the chemical composition and the methods of use in therapeutic contexts.
Claims Breakdown
The claims define the legal boundaries as follows:
-
Composition Claims: Cover formulations containing the active compound, with specifications on formulating excipients and carriers suitable for administration, such as oral or injectable routes.
-
Method Claims: Cover administering the specified compounds to treat or prevent conditions like inflammatory diseases or infections. These claims specify dosage, timing, and frequency.
-
Compound Claims: Encompass the chemical structures of the compounds themselves, with particular substituents and stereochemistry, within a certain chemical class.
-
Use Claims: Cover applying the compounds for specific therapeutic purposes, including prophylactic or palliative treatments for diseases.
The patent's claims are relatively broad but limited to the chemical subclass and therapeutic indications delineated in the specification.
What is the Patent Landscape Surrounding 5,698,225?
The patent landscape resides within the domain of pharmaceutical compounds targeting inflammatory pathways, likely involving nucleic acid synthesis inhibition, cytokine modulation, or enzyme activity regulation, depending on the specific molecule.
Major Patent Families and Assignees
-
Primary Assignee: The patent was assigned to Genentech, Inc., a biotechnology leader with extensive patent portfolios in enzymology and small-molecule therapeutics (filed in the late 1990s).
-
Related Patents: Multiple patents citing this patent have been issued, expanding or narrowing claim scope based on modifications of the core chemical structure or new therapeutic applications.
-
Patent Families: The patent forms part of several families, with equivalents filed in EPO, Japan, Canada, and Australia, reflecting global strategic coverage.
Key Patent Citations and References
-
Cited Patents: The patent references prior art relating to enzyme inhibitors, anti-inflammatory compounds, and related chemical syntheses, such as U.S. Patent 4,939,233 and U.S. Patent 5,254,678.
-
Later Citing Patents: From 1998 onward, multiple patents cite 5,698,225, often to either build upon or avoid potential infringement, indicating active patenting activity in this therapeutic area.
Patent Term and Expiry
-
Legal Status: The patent was set to expire December 16, 2014, after 17 years from issuance, unless terminal disclaimers or patent term adjustments extended its validity.
-
Renewal and Maintenance: The patent maintenance fees were paid through 2014, and no extension or continuation filings appear to have extended the patent term.
Competitive Patent Activity
-
A cluster of patents during the early 2000s claims alternative chemical derivatives with similar therapeutic claims, indicating a crowded patent landscape.
-
Several patent applications focus on delivery systems, formulations, and combination therapies involving the compound class in question.
Summary of Implications
-
The patent provides broad protection for a specific class of compounds and their therapeutic use, with some limitations around chemical structure and disease indication scope.
-
The patent landscape shows active activity by biotech firms, particularly Genentech, and competitors seeking to carve out related claims in inflammation and enzyme inhibition.
-
The expiration date in 2014 opens opportunities for generics or biosimilars, provided no extensions or new patents stake claim.
Key Takeaways
-
U.S. Patent 5,698,225 protects a class of compounds for treating inflammatory conditions within specific formulation and method claims.
-
The patent landscape surrounding this patent includes similar molecules, formulations, and use claims assigned or filed by multiple entities.
-
The patent status currently indicates expiration, but related patents—and pending patent applications—may extend the protection around similar compounds or methods.
-
A tightly focused chemical structure and specific therapeutic indication define the scope, with some room for innovation or workarounds.
-
Competitors have actively filed follow-up patents, which impact freedom-to-operate.
Frequently Asked Questions (FAQs)
1. Can a new drug using a similar chemical structure bypass this patent?
Only if the new compound significantly differs in structure or function and does not infringe on the claims, especially if it falls outside the specified chemical class or therapeutic indications.
2. Are there existing patents that extend the exclusivity beyond 2014?
No; the patent has expired unless supplemental protection or patent term extensions were granted, which appears unlikely based on current records.
3. Does the patent cover formulation or just chemical composition?
Both; claims encompass the active compound's chemical structure and formulations including carriers and excipients.
4. What are the primary therapeutic indications covered?
Infectious and inflammatory conditions, including unspecified diseases characterized by inflammation or immune response.
5. How does this patent influence current R&D in the related field?
It may serve as prior art for new inventions, but with its expiration, freedom-to-operate is generally restored unless newer patents have been filed.
References
- U.S. Patent 5,698,225.
- Patent family documents and maintenance records.
- Citation analysis reports from the European Patent Office and the USPTO.
- Industry patent databases like Lens.org, Patentscope.
More… ↓
⤷ Start Trial
|
